| NCT07073183 | Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) | NOT_YET_RECRUITING | PHASE1 | 2025-07-30 | 2029-12-31 | 2029-12-31 |
| NCT05938387 | Safety and Tolerability of CVGBM in Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-06-01 | 2026-02-04 | 2026-02-04 |
| NCT05252338 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults | COMPLETED | PHASE1 | 2022-02-07 | 2022-09-27 | 2022-09-27 |
| NCT04838847 | A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 | WITHDRAWN | PHASE3 | 2021-10-01 | 2022-09 | 2022-01 |
| NCT04860258 | COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities | TERMINATED | PHASE3 | 2021-04-22 | 2021-09-21 | 2021-09-21 |
| NCT04674189 | A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 | COMPLETED | PHASE3 | 2020-12-23 | 2022-06-08 | 2022-06-08 |
| NCT04652102 | A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older | COMPLETED | PHASE2, PHASE3 | 2020-12-11 | 2022-06-10 | 2022-06-10 |
| NCT04515147 | A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 | COMPLETED | PHASE2 | 2020-09-21 | 2022-02-21 | 2022-02-21 |
| NCT04449276 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 | COMPLETED | PHASE1 | 2020-06-18 | 2021-12-21 | 2021-12-21 |
| NCT03713086 | A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults | COMPLETED | PHASE1 | 2018-10-12 | 2021-11-23 | 2021-11-23 |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | UNKNOWN | PHASE1 | 2017-09-25 | 2023-02 | 2022-10 |
| NCT02238756 | Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults | COMPLETED | PHASE1 | 2014-09 | 2016-11 | 2015-09 |
| NCT02140138 | An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer | TERMINATED | PHASE2 | 2014-06 | 2016-04 | 2016-04 |
| NCT02241135 | RNActive® Rabies Vaccine (CV7201) in Healthy Adults | COMPLETED | PHASE1 | 2013-10 | 2018-02-08 | 2018-02-08 |
| NCT01915524 | Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC) | TERMINATED | PHASE1 | 2013-04 | 2016-07 | 2016-07 |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | TERMINATED | PHASE1, PHASE2 | 2012-08 | 2017-01 | 2016-08 |
| NCT00923312 | Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE1, PHASE2 | 2009-05 | 2014-05 | 2012-02 |
| NCT00831467 | Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease | COMPLETED | PHASE1, PHASE2 | 2009-01 | 2013-09 | 2009-12 |